Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24840271 | 1.00 | NLRP3 (0.84) | NLRP3IL1B | |
| SCHEMBL30108903 | 0.98 | NLRP3 (0.81) | NLRP3IL1B | |
| SCHEMBL24575612 | 0.98 | NLRP3 (0.81) | NLRP3IL1B | |
| SCHEMBL24575129 | 0.98 | NLRP3 (0.81) | NLRP3IL1B | |
| SCHEMBL29276248 | 0.97 | NLRP3 (0.80) | NLRP3IL1B | |
| SCHEMBL29275826 | 0.97 | NLRP3 (0.80) | NLRP3IL1B | |
| SCHEMBL30214107 | 0.97 | NLRP3 (0.80) | NLRP3IL1B | |
| Formic Acid SCHEMBL29275648 | 0.96 | NLRP3 (0.78) | NLRP3IL1B | |
| Formic Acid SCHEMBL29275822 | 0.94 | NLRP3 (0.75) | NLRP3IL1B | |
| SCHEMBL29275533 | 0.93 | NLRP3 (0.74) | NLRP3IL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | claimed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | claimed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | claimed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | claimed |
| US-20250002470-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | ZHEJIANG AIXPLORER BIOTECH CO., LTD. (CN) | 2025-01-02 | — | — | US | disclosed |
| US-20240391895-A1 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | QINGDAO BORSON TAI TECHNOLOGY CO., LTD. (CN) | 2024-11-28 | — | — | US | disclosed |
| US-20240327413-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD | 2024-10-03 | — | — | US | disclosed |
| EP-4421068-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Zhejiang Aixplorer Biotech Co., Ltd. (CN) | 2024-08-28 | — | — | EP | disclosed |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | PCT THERAPEUTICS, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| CN-118302417-A | NLRP3 inhibitors | PTC医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4392414-A1 | INHIBITORS OF NLRP3 | PTC Therapeutics, Inc. (US) | 2024-07-03 | — | — | EP | disclosed |
| EP-4362946-A1 | NLRP3 MODULATORS | Zomagen Biosciences Ltd (US) | 2024-05-08 | — | — | EP | disclosed |
| CN-117881401-A | NLRP3 modulators | 祖玛珍生物科学有限公司 | 2024-04-12 | — | — | CN | disclosed |
| CN-116390914-A | Pyridazine-containing compound and medical application thereof | 上海拓界生物医药科技有限公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-116102535-A | Nitrogen-containing compound, preparation method and application thereof | 索智生物科技（浙江）有限公司 | 2023-05-12 | — | — | CN | disclosed |
| WO-2023066377-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 索智生物科技（浙江）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| WO-2023028534-A1 | INHIBITORS OF NLRP3 | PTC THERAPEUTICS, INC. (US) | 2023-03-02 | — | — | WO | disclosed |
| WO-2023278438-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2023278438-A1 | NLRP3 MODULATORS | ZOMAGEN BIOSCIENCES LTD (US) | 2023-01-05 | — | — | WO | disclosed |
| WO-2022135567-A1 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | 上海拓界生物医药科技有限公司 | 2022-06-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240391895-A1 | PYRIDAZINE-CONTAINING COMPOUND AND MEDICINAL USE THEREOF | NLRP3, NLRP1, NOD1 | NLRP3 1/4885IL1B 6/4885 |
| US-20240262806-A1 | INHIBITORS OF NLRP3 | NLRP3, NOD1, NLRP1 | NLRP3 1/4885IL1B 10/4885 |
| US-20250002470-A1 | NITROGEN-CONTAINING COMPOUND, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | NOD1, NLRP3, NLRP1 | NLRP3 2/4885IL1B 9/4885 |
| US-20240327413-A1 | NLRP3 MODULATORS | NLRP3, NLRP1, NOD1 | NLRP3 1/4885IL1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.